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Summary
We tested whether nonspecific tumoricidal immune cells can suppress congenital malformations
by killing precursor cells destined to cause such defects. Pretreatment ofpregnant ICR mice
with synthetic (Pyran copolymer) and biological (Bacillus Calmette-Gu6rin) agents significantly
suppressed radiation- and chemical-induced congenital malformations (cleft palate, digit anomalies,
tail anomalies, etc.). Such suppressive effects were associated with the activation of maternal
macrophages by these agents, but were lost either after the disruption of activated macrophages
by supersonic waves or by inhibition of their lysosomal enzyme activity with trypan blue. These
results indicate that a live activated macrophage with active lysosomal enzymes can be an effector
cell to suppress maldevelopment. A similar reduction by activated macrophages was observed
in strain CL/Fr, which has a high spontaneous frequency of cleft lips and palates. Furthermore,
Pyran-activated maternal macrophages could pass through the placenta, and enhanced urethane-
induced cell killing (but not somatic mutation) in the embryo. It is likely that a maternal
immunosurveillance system eliminating preteratogenic cells allows for the replacement with normal
totipotent blast cells during the pregnancy to protect abnormal development.
During embryonic development, the different cell types
become determined in their proper places, and the pat-
tern of the body is set up on a small scale and then grows
(1). The appearance of outliers in such processes can result
in congenital malformations, but such outliers are effectively
reduced or eliminated by homeostatic surveillance mechanisms.
In experimental animals, radiation- and chemical-induced and
spontaneously developed malformations are cured or prevented
by vitamins (2, 3), caffeine (2, 4-6), and other bioresponse
modifiers (2, 7), probably due to normalization, or more likely
to killing of the damaged cells responsible for maldevelop-
ment. It is expected that such cellular alterations responsible
for producing congenital malformations in the embryos are
also under the control of the immunosurveillance system of
the pregnant animals (7) . In the present study, pregnant mice
were pretreated with Pyran copolymer and Bacillus Calmette-
Guerin (BCG)l vaccine which are known to activate mac-
rophages (8, 9), or they were post-treated with macrophages
activated by these agents, and then examined to determine
whether such immunological treatments can suppress
radiation- and chemical-induced, and also spontaneously de-
veloping, congenital malformations. Furthermore, placental
transfer of maternal macrophages and their effects on em-
1 Abbreviations used in this paper . BCG, Bacillus Calmette-Guerin; MNU,
N-methyl-N-nitrosourea.
bryonic mutation and cell killing were examined with specific
tester strains of mice.
Materials and Methods
Mice .
￿
ICR (F.,,,) and CL/Fr (F2o+24) mice were used for de-
tecting congenital malformations, and PT and HT mice for de-
tectingin vivo somatic mutation and cell killing. Inbred ICR mice
were established by T Nomura. CL/Fr mice were provided by Dr.
K. Esaki (Central Laboratoryfor Experimental Animals, Kanagawa,
Japan) at F2o, and then maintained by brother x sister mating
(Department of Radiation Biology, Osaka University). Approxi-
mately 30% of CL/Fr mice develop cleft lips and palates spontane-
ously (2). PT and HT mice were provided by Dr. M. F. Lyon and
Dr. A. G. Searle (Radiobiology Unit, Medical Research Council,
Harwell, UK) in 1978, and were maintained by brother x sister
inbreeding (Department of Radiation Biology, Osaka University).
Coat color genes ofthese mice were a/a, b/b, ptrl/pel, and d/d for
PT, and a/a, Im/ln, pa/pa, andpe/pe for HT Mice were maintained
with mouse diet CRF-1 (Charles River Japan, Kanagawa, Japan)
and chlorinated water in the complete barrier condition at 23 ±
10C. An estrous female (2 mo old) was selected by the appearance
of her vaginal orifice, and mated with males in the evening. The
next morning, a vaginal plug was examined to determine the first
day ofpregnancy (day 0) (2-5, 10). The mouse room was illumi-
nated from 4:00 to 18:00 so that fertilization occurred at about
2:00 on the day of a vaginal plug (2, 3, 10).
X-RayExposure
￿
X-irradiation (KC-18-2A; Toshiba, Tok)o, Japan)
was performed at a distance of 51.5 cm, operating at 20 mA and 180
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average dose rate was 0.54 Gy/min. The dose was measured by
an r-meter (570; Victoreen, Inc., Cleveland, OH) adjustedby Fricke
dosimetry.
Chemicals.
￿
Urethane andN-methyl-N-nitrosourea (MNU)were
used for inducing congenital malformation. Urethane (ethyl car-
bamate; Wako Pure Chemical Ind. Ltd., Osaka, Japan) was dis-
solved in distilledwater in a 10%concentration, andMNU(Sigma
Chemical Co., St. Louis) in 0.1 M sodium phosphate buffer solu-
tion (pH 5.8)in a0.1% concentration. These solutions were pre-
pared just before injection.
To activate macrophages, Pyran copolymer (XA 146-85-2, NSC
46015; Hercules Research Center, Wilmington, DE) and freeze-
dried glutamateBCG (Japan BCGLab., Tokyo, Japan) were used.
Pyran copolymerwasdissolved in a0.9% NaCl solution, and the
pH of the solution was adjusted to 7.2 with a 10% NaOH solu-
tion. The final concentration of the Pyran copolymer in a 0.9%
NaCl solution was 0.01, 0.1, and 0.5%. BCG was suspended in
a 0.9% NaCl solution at a 0.1% concentration.
Pretreatment with Pyran andBCG before ICRayor Chemical Treat-
ment. Pyran copolymerwas injected intraperitoneally into preg-
nant ICR mice on day 3 of gestation at a dose of 0, 1, or 10 FAg/g,
andthen 1.23, 1.43, or 1.85Gy of X-rays, or asingle subcutaneous
injection of urethane (1.0 mg/g) or MNU (10 tag/g) was given
at 14:00 on day 9 of pregnancy. Macrophage activation measured
by tumoricidal effects becomes maximum6 d after intraperitoneal
injection of Pyran copolymer (9). BCG (10 tag/g) was injected in-
traperitoneally into female ICR mice (2 mo old), and then they
were mated with ICR males at various intervals from 6 to 46 d
after BCG treatment. Pregnant mice were treated with urethane
(1.0 mg/g) or X rays (1.43 Gy) at 14:00 on day 9.
Collection ofPeritonealMacrophages.
￿
Pyrancopolymer (50tag/g)
was injected intraperitoneally into adult (2-mo-old) ICRmice, and
peritoneal exudates were collected6 d afterPyran treatment, since
macrophage activation measured by tumoricidal effects becomes
maximum on that day (9). Cells were washed once with an ice-
cold 0.9% NaCl solution and resuspended in Whitten's embryo
culture medium (3 ml/mouse) (11). Peritoneal macrophages were
purified by adherenceon tissue culture dishes. After 1 h ofincuba-
tion at 37°C in 5% COz and air, adherent cells were gently
scraped with a soft rubber policeman into Whitten's medium, ad-
justed to 107 viable cells per ml, and kept in an ice bath before
use. More than 95% of the cells prepared in this manner ingest
dextran sulfate, which was stained metachromaticallyby toluidine
blue 0 (Chroma, Stuttgart, FRG) (8). For thecollection ofnormal
macrophages, glycogen (0.5 mg/g, Wako Pure Chemical Ind. Ltd.),
instead of Pyran, was injected intraperitoneally into 2- or 12-mo-
old ICRmice. For the disruption of activated macrophages by su-
personic waves, cells were treated with a sonifier disruptor (B-12;
Branson Sonic Power Co., Danbury, CT) at 20 kHz for 30 s in
an ice bath. Microscopically, no cells were detected. To inhibit the
activity of lysosomalenzymes ofactivated macrophages, trypan blue
(100 tag/g, Wako Pure Chemical Ind. Ltd.) was injected in-
traperitoneally into 2-mo-old ICR mice 48 h before collection of
peritoneal exudates (8). Activatedperitoneal macrophages were also
collectedfrom PT and CL/Frmice treated intraperitoneally with
50 tag/g of Pyran and purified by adherence on culture dishes as
described above.
Peritoneal macrophages were also collected 35 or 45 d after in-
traperitoneal injection of BCG (10 tag/g), purified, and adjusted
to 10' viable cells/ml. These activated or normal (nonactivated)
macrophages (5 x 1( 6 cells/mouse) were injected intravenously
into pregnant ICR mice 0.5 or 48 h afterurethane or X-raytreat-
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ment at 14:00on day9of pregnancy. Pyran-activated macrophages
(5 x 106 cells/mouse) were also injected intravenously into preg-
nant CL/Frmice on day9, acritical stageforinducing congenital
malformations by radiation and chemicals (2-5).
Examination ofCongenital Malformations.
￿
Pregnant ICR mice
were killed on day 18 of gestation by cervical dislocation. After
hysterectomy, implants, earlydeaths, late (fetal) deaths, and living
fetuses were recorded. Living fetuses were weighedand examined
for external malformations and for skeletal malformations using
asoft X-rayapparatus (SOFRONType SRO-M50; Sohken, Tokyo,
Japan). Details of theseprocedures were reported previously (2-5).
Thepredominant typesofinduced congenital malformations were
cleft palate, tail anomalies (kinky and short), and digit anomalies
(poly-, olygo-, or syndactyly). Pregnant CL/Fr mice were killed
on day 17 to detect both cleft lip and cleft palate.
Detection of In Vivo Somatic Mutation and Cell Killing.
￿
An es-
trous PT female was mated with HT males. Pregnant PT females
were treated subcutaneously with urethane (1.0 mg/g) at 14:00 on
day 10, and 0.5 h later, 5 x 106 Pyran-activated macrophages were
injected intravenously into halfofthem. Concurrent controls were
not treatedwith urethane or activated macrophages. Activated mac-
rophages werecollected from PT mice treatedintraperitoneally with
50 lag/g of Pyranand purified by adherence on culture dishes. So-
matic mutation and cell killing were detected as coat color spots
6 wk after birth. When a mutation occurred in a melanoblast of
the [PT x HTIF, (hereafter designated PTHTF,) embryo hetero-
zygous at seven coat color genes (a/a, In/+ , pa/+, b/+ ,
pc,ll+ + , d/+, pe/+ ), a spot with different coat color, which
derived from the mutated melanoblast, appears on the nonagouti
black background after birth. Killing of a melanoblast results in
a pigment vacancy in the hair, and a white spot appears on the
ventral midline of the coat (white miciventral spots) (5, 12). De-
tails of the experimental procedures were reported previously (5).
Results
Suppression ofX-Ray-, Urethane-, andMNU-inducedMafor-
mations by Pyran Pretreatment. Pyran copolymer (1 and 10
Ag/g) was injected intraperitoneally into pregnant ICRmice
on day 3 of gestation, before X-ray or chemical treatment
on day 9, when macrophage activation by Pyran becomes
maximum. As shownin Fig. 1, X-ray-inducedcongenital mal-
formations were suppressed slightly but significantly by the
Pyranpretreatment at ahigh dose. 98.6% of theX-ray-induced
malformations were tail anomalies, some of which were ac-
companiedwith meningoceles (1.9%) . Theremainders were
cleft palates (0.7%), digit anomalies (0.4%), gastroschises
(0.12%), and exencephalus (0.06%). More dramatic reduc-
tionswere observed with urethane- andMNU-induced cleft
palates, tail anomalies, and digit anomalies. Pyran pretreat-
ment reduced40-100% ofurethane- andMNU-induced con-
genital malformations. However, Pyran pretreatment reduced
neither the average number of living fetuses (see legends to
Figs. 1, 2, and 4, and Table 1) nor average body weight of
the fetuses (data not shown).
Suppression of Urethane- andXRay-induced Congenital Mal-
formations by Pyran-activatedMacrophages. To examine the as-
sociation of macrophage activation with antiteratogenic ac-
tivityby Pyran, peritoneal macrophages that hadbeen activated
by Pyran and purified by adherence on tissue culture dishese
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Figure 1.
￿
Suppression of X-ray-, urethane-, and MNU-induced con-
genital malformations by the pretreatment with Pyran copolymer. (X-rays)
Histograms for the total incidence of congenital malformations (mostly
tail anomalies, see text) at X-ray doses of 1.23, 1.43, and 1.85 Gy. (Ure-
thane) Histograms for cleft palates (CP), tail anomalies (TA), and polydac-
tylies (PD). (AMU) Histograms for cleft palates, tail anomalies, polydac-
tylies, and oligo-syn-dactylies (OD). The number of fetuses examined
(pregnant mice in parentheses) is 129 (11), 150 (14), and 111 (10) for 1.23
Gy of X-rays; 198 (18), 99 (11), and 130 (11) for 1.43 Gy; and 89 (10),
107 (11), and 91 (11) for 1.85 Gy at 0, 1, and 10 P,g/g of Pyran, respec-
tively. For urethane, the number is 155 (14), 114 (10), and 141 (13) at 0,
1, and 10 Wg/g of Pyran; and for MNU, 118 (11) and 125 (11) at 0 and
1 ug/g of Pyran, respectively. Vertical bars indicate 90% confidence in-
tervals ofthemean computed from thet distribution of malformed fetuses
in each litter. (*)p < 0.05; (**)p < 0.01 against experimental groups
without Pyran treatment. A student's t test was applied after testing vari-
ance ratio.
were injected intravenously into pregnant mice afterurethane
or X-ray treatment on day 9 (Fig. 2). Urethane- and X-ray-
induced congenital malformations were significantly sup-
pressed by the activated macrophages injected 0.5 h after treat-
ment. Normal macrophages that were elicited by glycogen
and purified similarly had no effect on malformation frequency.
Such suppressive effects of activated macrophages on congenital
malformations diminished or disappeared when macrophages
were injected 48 h after urethane or X-ray treatment, sug-
gesting that the teratogenic process was determined during
these periods. It is noted that such suppressive effects ofacti-
vated macrophages disappeared after the disruption of cells
by supersonic waves. When Pyran-activated macrophages were
treated in vivo with trypan blue, an inhibitor of lysosomal
enzymes, 48 h before collection, they did not suppress con-
1327
￿
Nomura et al.
60
40
20
Urethane
N
C
O
A 0
None n-MO a-MO; a-NO; a-NO ; a-MO;
0 0 .5h 48h disrup Try-B
w
e X-rays
;,
￿
6oT
~,
4.11 1 I
￿
ffl
￿
I
￿
I
￿
T
U
20
0
None n-MO a-MO ; a-MO;
￿
n-MO;
0 .5h 48h
￿
old
Figure 2.
￿
Association ofmacrophage activationby Pyran with the sup-
pression ofurethane- and X-ray-induced congenital malformations. Preg-
nant ICR mice were treated with 1.0 mg/g of urethane or 1.43 Gy of
X-rays at 14:00 on day 9, and then received intravenous injection of 5 x
106 activated macrophages (a-MO) (107 cells/ml) 0.5 or 48 h after ure-
thane or X-ray treatment. Equal numbers of normal (glycogen-elicited)
macro hages (n-MO) and disrupted (a-MOdisnrnp) or trypan blue-treated
(a-M7,T ;B)activated macrophages were also injected intravenously into
pregnant mice 0.5 h after urethane or X-ray treatment. Macrophages elicited
by glycogen from 12-mo-old non-SPF ICR mice were also injected 0.5 h
after X-ray exposure (n-MOvld). The number of fetuses (pregnant mice)
examined was 247 (23), 111 (11), 151 (12), 155 (14), 129 (11), and 195
(17) for urethane-treated groups with no macrophages (None), n-MO,
a-MO;0.5 h, a-MO;48 h, a-MO;disrup, and a-MOTry-B, respectively, and
198 (18), 153 (14), 131 (11), 161 (14), and 140 (12) for X-ray-treated groups
with no macrophages (None), n-M0, a-MO;0.5 h, a-MO;48 h, and
n-MO;old, respectively. Vertical bars indicate 90% confidence intervals
of the mean. Urethane: (®) cleft palate; (/) tail anomaly; (0) polydac-
tyly. X-rays: mostly tail anomalies (see text). (*)p < 0.05; (* *)p < 0.01
against urethane- or X-ray-treated groups without macrophages (None)
and also with normal macrophages (n-MO).
genital malformations (Fig. 2). These results indicate that
a live activated macrophage with functioning lysosomal en-
zyme activities can be the critical effector cell for the sup-
pression of congenital malformations.
Suppression ofSpontaneously Developing Malformations by Ac-
tivated Macrophages. A reduction of congenital malforma-
tions was observed similarly in strain CL/Fr, which has a
high spontaneous frequency of cleft lips and palates. When
Pyran-activated macrophages were injected intravenously into
pregnant CL/Fr mice on day 9 (the critical stage for induc-
tion ofcleft palates), the incidence of congenital malforma-
tions (35 cleftlips [18.2%] and 34 cleft palates [17.7%] among
192 fetuses) was significantly suppressed in comparison with
that of untreated controls (58 cleft lips [28.2%] and 61 cleft
palates [29.6%] among 206 fetuses; p < 0.02).
Suppression ofCongenital Maformations by BCG and BCG-
activated Macrophages.
￿
Similar effects on congenital malfor-mations were observed with a biological agent, BCG vac-
cine (Fig. 3). Pretreatment with BCG significantly suppressed
urethane- and radiation-induced malformations even when
it was injected 6-46 d before pregnancy, although such sup-
pressive effects of BCG were prominent on cleft palates and
tail anomalies, but not on polydactylies. BCG-activated peri-
toneal macrophages collected -40 d after BCG injection also
suppressed urethane- and X-ray-induced congenital malfor-
mations. It is likely that chronic BCG infection could con-
tinuously activate macrophages to suppressmaldevelopment.
Moreover, normal macrophages collected from older (12
mo of age) mice nursed in the conventional mouse rooms
did suppress X-ray-induced malformations, although those
collected from 2-mo-old mice in the SPF condition did not
show significant suppressive effects (Fig. 2).
Effects ofActivated Macrophages on Urethane-induced Somatic
Mutation and Cell Killing. To ascertain the mechanism, a
specific tester strain (PTHTFt) of mice was used for de-
tecting somatic mutation and cell death of the melanoblast
in the embryo. As shown in Table 1, a large and significant
increase ofurethane-initiated cell deaths was observed by the
intravenous injection of Pyran-activated macrophages, while
activated macrophages showed no effects on the untreated
embryo. However, activated macrophages did not affect the
incidence of somatic mutation in both urethane-treated and
untreated embryos. Consequently, it is strongly suggested
that activated macrophages killed susceptible target cells with
urethane-induced cellular (but not DNA) alterations for mal-
development .
Detection ofActivated Macrophages in the Embrya
￿
To confirm
the placental transfer of immune cells, activated and normal
macrophages were first labeled with dextran sulfate, injected
intravenously into pregnant ICR mice on day 9, which were
killed 0.5-24 h later. About 75,000 serial sections were stained
by toluidine blue. As shown in Fig. 4, metachromatically
stained macrophages were first found in the maternal blood
Figure 3.
￿
Suppression of ure-
thane- and X-ray-induced malfor-
mations byBCGpretreatment and
its association with macrophage
activation. Pregnant mice were
treated with urethane (1.0 mg/g)
or X-rays (1.43 Gy) on day 9. The
number of fetuses (pregnant mice)
examined was 247(23), 91(8), 258
X-rays
￿
(26), 227 (22), and 141 (11) for
urethane-treated groups without
BCG (None), with BCG given 15,
35, or 55 d before urethane injec-
tion (BCG;15d, BCG;35 d, BCG;
55 d), and with activated macro-
phages (a-MO;35d), respectively,
and 337 (30), 184 (18), and 143
(13), for X-ray-treated groups
without BCG (None), with BCG
given 45 d before X-ray exposure (BCG;45 d), and with activated macro-
phages collected 45 d after BCG injection (a-MO; 45 d), respectively. The
experimental procedures are given in Materials and Methods. See legends
to Figs. 1 and 2 for symbols and statistical analysis.
Urethane
20'
ff
0
None BCG; a-NB ;
45d 45d
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Table 1.
￿
Effects of Pyran-activated Macrophages on
Urethane-induced Somatic Mutation and Cell Killing
in the PTHTF, Mouse Embryo
An estrous PT female was mated with HT males. Pregnant PT (56 fe-
males) were treated subcutaneously with urethane (1.0 mg/g) on day
10, and 0.5 h later, 5 x 106 Pyran-activated macrophages were injected
intravenously into 27 of them. The remainders were not treated with
activated macrophages. Effects of Pyran-activated macrophages on spon-
taneous frequency ofsomatic mutation and cell killing were similarly ex-
amined. Details for the experimental procedures are given in Materials
and Methods.
" p < 0.01 by X2 test against urethane-treated group without activated
macrophages.
flow, and 6 h later, detected in the chorionic villi of the fetal
placenta, indicating that macrophages can pass through the
placental barrier. A few cells with metachromatic granules
of dextran sulfate were found in the blood flow and intersti-
tial tissue of the embryo.
Discussion
Synthetic and biological agents that activate macrophages
of host (pregnant) animals, and also resultant activated mac-
rophages, curedboth physically and chemically induced con-
genital malformations. Such suppressive effects of activated
macrophages were not limited to radiation- and chemical-
induced malformations, but extend to spontaneously de-
veloping congenital malformations. It is likely that activated
macrophages killed precursor cells destined to cause congen-
ital malformations. Such preteratogenic cells may be subse-
quently eliminated by macrophages and replaced by a normal
totipotent blast cell, which plays its proper part in the mul-
ticellular society. Although the average number of living fe-
tuses and their average body weight (data not shown) were
not reduced by treatment with Pyran, BCG, or activated mac-
rophages in the present study, cell destruction and replace-
ment may cause postnatal functional damage in cured new-
borns, e.g., reduced life span, loss of immune competence,
dementia, and so on. Such studies will be done in the future.
The problem is how activated macrophages can make con-
tact with outliers. Chemicals of high molecular weight
(>600) are known not to penetrate theplacental barrier (13),
but a possible placental transfer of some maternal immune
cells has been suspected in man and mice (14, 15). In the
present study, maternal macrophages could pass through the
Urethane
Activated
macrophage
Frequency
Somatic mutation
per mouse
Cell killing
mglg
1 .0 0 25/195 (0.13) 12/195 (0.06)
1.0 5 x 106 29/190 (0.15) 33/190 (0.17)'
0 0 6/294 (0.02) 1/294 (0.003)
0 5 x 106 1/84 (0.01) 0/84 (0.0)Placenta, and a few were found in the embryo (Fig. 4) . In
contrast to chemical substances, living cells with amoeboid
movements could pass through the trophoblast layer of the
placental villus. However, it is still questionable whether such
a small number of macrophagescan kill preteratogenic cells,
if direct contact with target cells is required for cell killing
(8). Some unknown mechanisms might be involved in the
suppression of congenital malformations by maternal mac-
rophages.
It is notedthat macrophages elicited by glycogen from aged
Figure 4 .
￿
Placental transfer ofacti-
vated macrophages. Dextran sulfate (25
pg/g; Pharmacia Fine Chemicals, Upp-
sala, Sweden) was injected intraperi-
toneally 24 h before the collection of
Pyran (50 pg/g)-activated or normal
macrophages (8). 107 cells were in-
jected intravenously intopregnant ICR
mice onday 9, and mice werekilled 0 .5,
2.5, 5, 6, and 24 h afterinjection . Serial
sections ofthepregnant uteri were made
and stained by toluidine blue 0 . (A)
Macrophages stained metachromatically
by toluidine blue (arrows) were seen in
the capillary of the alveolar wall at 0.5,
2.5, 5, and6 h after intravenous injec-
tion, but not after 24 h (x450) . (B)
Macrophages in the chorionic villi of
the fetal placenta . Metachromatic cells
are seen in the fetal chorionic villi
(arrows) bathed in the maternal blood
(m) 6 h after injection . g, giant cells
(x450) . (C) Macrophages in the sinus
venosus of the day 9 embryo (arrows)
(x450) . (D) Metachromatic cell in the
interstitial tissue of the day 9 embryo
(arrow) (x225) .
mice nursed in the conventional mouse rooms did suppress
X-ray-induced malformations, but those collectedfrom young
mice nursed in the SPF condition had little or no effect (Fig .
2) . As in thecase ofBCG, potential infection may have acti-
vated macrophages slightly in non-SPF-aged mice . Conse-
quently, it is not unreasonable to conclude that this ho-
meostatic immunosurveillance system eliminating outliers
(preteratogenic cells) can be naturally programmed for the
protection ofabnormal development in man andanimals that
are continuously exposed to biological modifying agents .
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